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Abstract 13	
Methylamines are biologically-active metabolites present in serum and urine samples, which 14	
play complex roles in metabolic diseases. Methylamines can be detected by proton nuclear 15	
magnetic resonance (NMR), but specific methods remain to be developed for their routine 16	
assay in human serum in clinical settings. Here we developed and validated a novel reliable 17	
“methylamine panel” method for simultaneous quantitative analysis of trimethylamine 18	
(TMA), its major detoxification metabolite trimethylamine-N-oxide (TMAO), and precursors 19	
choline, betaine and L-carnitine in human serum using Ultra Performance Liquid 20	
Chromatography (UPLC) coupled to High Resolution Mass Spectrometry (HRMS). 21	
Metabolite separation was carried out on a HILIC stationary phase. For all metabolites, the 22	
assay was linear in the range of 0.25 to 12.5µmol/L and enabled to reach limit of detection of 23	
about 0.10µmol/L. Relative standard deviations were below 16% for the three levels of 24	
concentrations. We demonstrated the strong reliability and robustness of the method, which 25	
was applied to serum samples from healthy individuals to establish the range of 26	
concentrations of the metabolites and their correlation relationships and detect gender 27	
differences. Our data provide original information for implementing in a clinical environment 28	
a MS-based diagnostic method with potential for targeted metabolic screening of patients at 29	
risk of cardiometabolic diseases. 30	
 31	
Keywords: Trimethylamine, Trimethylamine-N-oxide, choline, betaine, L-carnitine, 32	
Cardiometabolic diseases   33	
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1. Introduction 34	
Metabolic profiling technologies enable detection and quantification of low molecular weight 35	
compounds in biological samples to enhance our understanding of gene function, disease 36	
mechanisms and drug treatments [1]. They represent powerful high-throughput and high-37	
density molecular phenotyping tools to uncover diagnostic and prognostic metabolic 38	
biomarkers [2]. Technological and methodological advances in the field provide opportunities 39	
in clinical settings to profile patient metabolism [3] and in genetic research to identify 40	
metabolites associated with complex diseases [4, 5]. 41	
There is increasing interest in methylamines in clinical and fundamental research. Variations 42	
in trimethylamine (TMA), the product of microbial metabolism of choline, and its 43	
detoxification metabolite, trimethylamine-N-oxide (TMAO), have been associated with 44	
nephrotoxin treatments [6], microbial colonization of germ-free rats [7], insulin resistance in 45	
mice [8] and cardiovascular disease in humans [9-11]. Butyrobetaine, another metabolite in 46	
this pathway derived from dietary L-carnitine, has also been proposed as a marker for 47	
atherosclerosis [12]. These findings suggest that the search for disease-associated metabolite 48	
biomarkers and gut microbial-mammalian co-metabolites should be extended beyond TMAO 49	
to other metabolites in the methylamine pathway. 50	
Untargeted high field proton nuclear magnetic resonance (NMR) spectroscopy is widely used 51	
for TMAO and choline analysis [13, 14] but detection limits (around 0.5x10-5M) make TMA 52	
quantification difficult in blood compared to mass spectrometry (MS). LC-MS/MS methods 53	
have been developed to individually assay TMAO [15], choline and betaine [16] and L-54	
carnitine and acylcarnitines compounds [17]. In addition, methods for quantitative analysis of 55	
TMA/TMAO and L-carnitine (Fast Atom Bombardment mass spectrometry (FAB-MS) [18, 56	
19], Metastable Atom Bombardment (MAB-MS) [20, 21], Matrix-Assisted Laser Desorption-57	
Time-of-Flight (MALDI-TOF) [22]) use analytical instruments uncommon in clinical 58	
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laboratories. GC-MS has also been used for indirect quantification of TMAO [23-25], but it 59	
requires TMA reduction and derivatization and is therefore time-consuming. Finally, flow 60	
injection electrospray ionization-mass spectrometry (FIA-MS) [26, 27] prevents addition of 61	
other compounds in the method without prior chromatographic technique. 62	
Here we developed a multiplexed MS-based method, which can be applied in both research 63	
and clinical settings for simultaneous quantitative analysis of TMA and four quaternary amine 64	
compounds (betaine, choline, TMAO and L-carnitine). It is based on HILIC ultra performance 65	
liquid chromatography coupled with high-resolution mass spectrometry (UPLC-HRMS). We 66	
assessed the sensitivity and reliability of the method, and tested its applicability in a group of 67	
healthy individuals.  68	
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2. Material and Methods 69	
2.1.Chemicals and reagents 70	
Certified pure trimethylamine hydrochloride (TMA), trimethylamine-N-oxide dihydrate 71	
(TMAO), betaine hydrochloride, L-carnitine hydrochloride, and choline chloride were 72	
purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). The corresponding stable 73	
isotopes used as internal standards of trimethylamine-13C, 15N, choline-d4, betaine-d3 and L-74	
carnitine-methyl-d3 were also obtained from Sigma-Aldrich. d3 labelled L-carnitine was 75	
purchased from Cluzeau Info Labo (Sainte Foy La Grande, France) and d9 labelled TMAO 76	
from Euriso-tope (Saint-Aubin, France). Formic acid and ammonium formate were LC-MS 77	
Chromasolv® Fluka, HPLC quality and purchased from Sigma-Aldrich. Ultra pure water 78	
(resistivity: 18 mΩ) was obtained with a Milli-Q Integral purification system (Millipore, 79	
Molsheim, France) with a 0.22 µm filter. Human and bovine sera were obtained from Life 80	
technologies (Saint-Aubin, France). 81	
2.2. Preparation of standard and calibration solutions 82	
Stock standard solutions were prepared in acetonitrile (CH3CN) for TMA, TMAO, choline 83	
and betaine at a concentration of 20mmoL/L. L-carnitine was dissolved in a mixture of 84	
acetonitrile/water (95:5) at a concentration of 20 mmol/L. Working solutions of the reference 85	
compounds mixture were prepared at concentrations of 100, 50 and 25µmol/L. Individual 86	
solutions for each stable isotope, associated to each native compound were prepared in the 87	
same conditions. A working solution mixture of stable isotope standards was set at a 88	
concentration of 100µmol/L. All standard solutions were stored at -20°C.  89	
2.3.Serum sample collection and preparation 90	
Human serum samples were prepared from blood of 67 healthy individuals (39 males and 28 91	
females aged 24-59 years) who were recruited from Boston area clinics and community health 92	
care centers. This study was approved by the institutional review board of Massachusetts 93	
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General Hospital and all individuals involved provided informed consent to participate. Work 94	
was carried out in accordance with The Code of Ethics of the World Medical Association 95	
(Declaration of Helsinki) for experiments involving humans. Samples were stored at -80°C 96	
until analysis. Sample preparation was based on protein precipitation and liquid-liquid 97	
extraction with acetonitrile (1:9, v:v). Proteins were eliminated by centrifugation and the 98	
supernatant was injected for analysis. Experiments were carried out with 50µL serum aliquots 99	
which were spiked with 100µL of a mixture of internal standards before completing to 500µL 100	
with acetonitrile. Samples were vortexed at 2500 rpm during 3 minutes with an automatic 101	
shaker (Heidolph©, VWR, Fontenay-sous-bois, France) and centrifuged at 4100g. Sample 102	
extracts were then transferred into vials for injection on the analytical system. 103	
2.4.Liquid chromatography 104	
Liquid chromatography was carried out on a Waters Acquity UPLC® (Waters Corp, Saint-105	
Quentin en Yvelines, France) equipped with a sample manager, a binary solvent delivery 106	
system and a PDA detector. The flow rate was 750µL/min and the injection volume was 5µL. 107	
The autosampler vial tray and the column temperatures were set at 5°C and 50°C, 108	
respectively. The needle was washed with a mixture of acetonitrile, isopropanol and water 109	
(1:2:1 v:v:v). The system was fitted with an Acquity BEH HILIC column (2.1×150 mm, 110	
1.7µm) and a corresponding guard column (ACQUITY BEH HILIC 1.7µm) purchased from 111	
Waters®. The mobile phase consisted of 10mM ammonium formate and 0.6% of formic acid 112	
(v/v) in water (A) or in 95:5 (v/v) CH3CN:Water (B). Mobile phase for HILIC 113	
chromatography was prepared by dissolving the appropriate amount of ammonium formate in 114	
water before mixing with acetonitrile. The HILIC gradient started at an initial composition of 115	
100% solvent A for 2 mins, followed by a 4 mins linear gradient up to 30% of solvent A, 116	
which was held for 1 min before returning to initial conditions in 1 min. The column was 117	
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thoroughly conditioned during 6 mins until the next injection, for a total chromatographic run 118	
time of 14 mins.  119	
2.5.Mass spectrometry 120	
The chromatographic system was coupled with a Q-Exactive™ hydrid quadrupole-Orbitrap 121	
mass spectrometer (Thermo Fisher Scientific, Illkirch, France). Instrument calibration was 122	
performed by infusing a calibration mixture (caffeine, MRFA and Ultramark® 1621). A 123	
heated-electrospray HESI-II interface was used with the following parameters : S-Lens 80 V, 124	
Sheath gas: 50, Auxiliary gas: 20 arbitrary units, capillary voltage 3.5kV, capillary 125	
temperature 255°C and vaporization temperature 320°C. The maximum target capacity of the 126	
C-trap (AGC) target was defined as 3e6 and the maximum injection time was set to 200ms. 127	
Full scan was acquired in positive ion mode with a resolution of 70 000 FWHM, in the scan 128	
range of m/z 50-400. The Xcalibur Quanbrowser software (Thermo Fisher Scientific, Illkirch, 129	
France) was used for quantification. Targeted analyte signals were extracted with a mass 130	
window accuracy < 0.5ppm.  131	
2.6.Method validation and matrix effect assessment  132	
The optimized method was validated by assessing the following parameters: linearity, limit of 133	
detection and quantification, precision, recoveries, accuracy and stability. Linearity was 134	
assessed with concentrations ranging from 0.25 to 12.5µmol/L in triplicate analysis. 135	
Instrumental limits of quantification (ILOQ) were determined by analyzing solutions from 136	
serial dilution of standards in ACN and were expressed as the lowest concentration yielding 137	
the signal-to-noise ratio of 10. Instrument limits of detection (ILOD) were defined by the 138	
lowest concentration detected in serial diluted solvent standards at a signal-to-noise ratio of 3. 139	
Method limits of quantification (MLOQ) and method limits of detection (MLOD) were 140	
evaluated by the lowest concentration, which could be detected in samples submitted to the 141	
entire analytical process with the same criteria as ILODs. To estimate precision, serum 142	
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samples spiked at 3 concentrations (1, 5 and 10µmol/L) were injected 10 times to evaluate 143	
repeatability. As no certified reference material exists for our specific method, accuracy was 144	
assessed by comparing spiked concentrations to effectively measured concentrations. 145	
Absolute recoveries were evaluated by triplicate analysis of serum spiked at a concentration 146	
of 5µmol/L. Solvent and serum calibration curves were compared. The matrix effect was 147	
characterized by either enhancement or suppression of an ion. Slopes of the calibrations 148	
curves were then compared to determine matrix effect. For stability studies, four serum 149	
sample aliquots kept frozen at -80°C were treated either immediately upon thawing or 150	
following one, two or three thaw-freeze cycles. Two further series of aliquots were stored at 151	
room temperature or refrigerated for 7 days. The latter was frozen at -80°C, thawed and 152	
extracted. All aliquots were then extracted and analysed. 153	
2.7.Statistical analysis 154	
Statistical analyses were performed using the Statistica® software (version 8.0) and R 155	
programming language. Descriptive statistics were performed for data treatment. Shapiro-156	
Wilk test of normality of the data was used before implementing the t-student test to evaluate 157	
precision.   158	
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3. Results 159	
3.1.Method development for HILIC-HRMS 160	
To optimize simultaneous assay of the selected metabolites by liquid chromatography prior to 161	
detection by MS, we considered primarily their physico-chemical properties and 162	
chromatographic separation and retention features. Betaine, choline, L-carnitine, TMA and 163	
TMAO have similar chemical structures containing a common trimethylamine group. 164	
Trimethylamine and the quaternary ammonium compounds studied here are polar compounds 165	
with a partition coefficient (log P) ranging from -4.52 to 0.06 (Table 1). For this reason, TMA 166	
and TMAO are poorly retained on the general stationary phase like C18, CN and phenyl 167	
columns and derivatisation is either necessary when using RP-HPLC [28], or not required 168	
when using polar stationary phases [15, 29]. Therefore Hydrophilic Interaction Liquid 169	
Chromatography (HILIC) appeared to be the most suitable column for their separation. HILIC 170	
stationary phase has been used for individual separation of TMAO, TMA and other nitrogen 171	
compounds [29]. The main advantages of HILIC in our study for simultaneous analysis of 172	
five low molecular weight compounds characterized by similar behavior in liquid 173	
chromatography, are its ability to separate polar compounds without derivatisation and to be 174	
coupled with mass spectrometry, thus allowing high sensitivity. 175	
Some source fragmentations could occur on all the compounds during ionization processes 176	
leading to the loss of the trimethylamine residue. Therefore chromatographic separation is 177	
required in order to avoid any contribution of any fragment signal to the trimethylamine 178	
residue initially present in the extract. To optimize the composition of the gradient, retention 179	
behavior of individual analytes was determined in isocratic mode by varying the amount of 180	
acetonitrile.  In these conditions, TMA, TMAO, choline and L-carnitine started to be 181	
separated around 90%, but a better separation was achieved at 95% with a highest dispersion 182	
of retention factors k (Fig. 1). Thus, experiments were carried out with 95% of acetonitrile as 183	
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an initial gradient composition. Liquid chromatography separation was further optimized by 184	
testing various mobile phases adjusted at 3 different pH. A compromise between sensitivity, 185	
peak shape and retention time was found for the 5 compounds at a pH adjusted to 186	
approximately 2. We determined that optimal conditions of flow rate (0.75mL/min) and 187	
column temperature (50°C) allowed separation of the analytes in less than 5 min (Fig. 2).  To 188	
avoid retention time shift, a minimum of 5 min reconditioning was recommended by the 189	
supplier, which considerably extended the final run time whilst ensuring reliable 190	
reproducibility. 191	
Following chromatographic separation, compounds were analysed by mass spectrometry 192	
using a Q-Exactive instrument (quadrupole coupled with an orbitrap system), which allows 193	
the application of various acquisition modes. In our experiments, acquisition was performed 194	
in full scan mode and mass spectrometry diagnostic signal was extracted with a mass 195	
accuracy < 0.5ppm. To optimize mass spectrometry detection parameters, such as S-lens, gas 196	
pressure and temperature, each standard compound prepared in ACN/H2O (50:50, v/v) at a 197	
concentration of 1 µg/mL, was directly infused in a mobile phase flow using a Tee system 198	
while varying parameters until highest sensitivity was obtained. A compromise was chosen to 199	
ensure sufficient sensitivity for each metabolite (parameters given in Experimental). 200	
3.2.Method validation 201	
To characterize performances of the method, we evaluated the following criteria: linearity, 202	
limits of detection (LOQ), precision, accuracy and recovery (see Experimental). Experiments 203	
were carried out with spiked human serum, which is a matrix containing naturally various 204	
amounts of the analytes. Therefore initial concentrations of the analytes in the non-spiked 205	
matrix were always subtracted from the calculated concentration of the spiked samples. All 206	
validation parameters are summarized in table 2. 207	
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The linearity was determined using linear regression model. For each compound the ratio 208	
analyte/internal standard was plotted against the spiked concentrations. The slope, intercept 209	
and determination coefficient were measured. The calibration curves showed excellent linear 210	
response with a mean coefficient of determination higher than 0.99 for all compounds tested 211	
(Table 2). The relative standard deviations calculated on the slopes for the triplicate analysis 212	
were <2% for TMAO, choline, L-carnitine and betaine and were therefore outstanding. Even 213	
though relative standard deviation for TMA linearity was higher (15%) it was considered as 214	
acceptable. ILOD ranged from 2nmol/L for choline to 10nmol/L for TMA, L-carnitine and 215	
betaine. Values of LODs were in good agreement with those found by other research groups 216	
on comparable instruments [16, 17, 30, 33]. 217	
The precision of the method was determined by comparing measures of spiked human serum 218	
at 3 concentrations obtained by two different operators. Repeatability was assessed by 219	
determining the relative standard deviations (RSD), which were all below 12%, with the 220	
exception  of those of choline compounds which nevertheless remained <16%. This 221	
difference on repeatability is due to the high endogenous concentration already present in the 222	
human serum sample used. RSD slightly reduced with increasing spiked concentrations, with 223	
a drop from 16% to 3% at 10µmol spiked concentration. Fetal bovine serum was also tested 224	
as blank matrix, but initial concentration of the 5 targeted analytes was considered too high. 225	
Accuracy of the method was assessed by comparing spiked concentrations to real 226	
concentrations determined after analysis, for 3 different levels of concentration. 227	
For all samples that underwent thaw and freeze cycles, RSD of compound signals varied 228	
between 1.5 and 5.1% and were not significantly altered by the number of thaw and freeze 229	
cycles. All analytes were stable when serum was kept refrigerated for 7 days. All analytes but 230	
choline were stable in serum left at room temperature. 231	
3.3.Matrix effect 232	
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To test our method for matrix effects, we carried out a post-extraction addition approach to 233	
compare retention times of native compounds and deuterium labeled internal standards. Since 234	
matrix effect can occur at different levels of concentrations, we compared both concentrations 235	
measured at each level of the calibration range with or without the matrix and correlation 236	
coefficients of the calibration curves. We showed that for each of the five metabolites tested, 237	
the slopes obtained were identical for native metabolites and deuterium labeled internal 238	
standards, thus demonstrating that the correction of matrix effects was achieved (Fig. 3A-E). 239	
Analysis of regression models showed a significant association of intensity ratio with 240	
concentrations in solvent and serum for all compounds (Fig. 3F). 241	
To assess similarity between the regression lines for each compound, we applied two different 242	
linear models (Table 3). In model 1, the ratio intensity is modeled as the dependent variable 243	
with matrix-type variable as the factor and concentration as the covariate. We did not find 244	
evidence of significant interaction between the two variables, suggesting that the slope of the 245	
regression between "concentration" and "intensity ratio" is similar for solvent and serum. 246	
Model 2 is more parsimonious and does not account for interaction. Results obtained with 247	
Model 2 show that the matrix type has a significant effect on TMAO (3.0 x 10-7), choline (1.1 248	
x 10-16), L-carnitine (2.6 x 10-15) and betaine (5.0 x 10-15) (Table 3) which can be interpreted 249	
as significant differences in intercepts between the regression lines of solvent and serum as 250	
illustrated in Figure 3. Comparisons of the two models using ANOVA show that withdrawal 251	
of the interaction does not significantly affect the fit of the model (Table 3). These data show 252	
that Model 2 is the most parsimonious and thereby regression lines are parallel (similar slope) 253	
for solvent and serum for all cases. Therefore the isotopic dilution coupled to UPLC-HRMS 254	
method enables to overcome the matrix effects. 255	
3.4.Application of targeted quantification of methylamines in human serum samples 256	
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To validate our analytical method by demonstrating its application in a clinical context, we 257	
profiled serum samples from 67 healthy subjects according to the analytical process we 258	
developed. There were no significant differences in age in males (44.2 ± 1.2 years) and 259	
females (47.2 ± 1.1 years). No significant correlations between metabolite concentrations and 260	
individuals’ age were found. Serum levels of L-carnitine, choline and TMAO were similar in 261	
males and females, whereas significant gender differences were observed for TMA and 262	
betaine. Serum concentrations of these metabolites were significantly more elevated in males 263	
than in females for betaine (6.97 ± 0.39 µmol/L and 5.84 ± 0.33 µmol/L; p=0.03) and TMA 264	
(0.73 ± 0.09 µmol/L and 0.34 ± 0.01 µmol/L; p<0.001). The range of serum metabolite levels 265	
is illustrated with box and whisker plots distribution of betaine, L-carnitine, choline, TMA 266	
and TMAO (Fig. 4). Even though serum levels were similar to those reported in the literature 267	
[16, 33], we were able to demonstrate the broad ranges of concentrations of betaine (3.01-268	
15.84 µmol/L), L-carnitine (2.75-9.96 µmol/L), choline (0.91-2.98 µmol/L), TMAO (0.16-269	
17.52 µmol/L) and TMA (0.29-1.66 µmol/L) in healthy individuals. 270	
Serum concentrations of the 5 metabolites measured in 67 subjects were further investigated 271	
by principal component analysis (PCA). The biplot for principal components 1 (PC1) and 2 272	
summarized 52.4% of the variation and was primarily influenced by betaine, L-carnitine and 273	
TMA (Fig. 5A). This indicates close correlation between serum concentrations for betaine and 274	
L-carnitine, which was assessed by regression analysis (p=0.0009) (Supplementary Fig. 1). In 275	
contrast, variations in L-carnitine and betaine were almost orthogonal to concentrations of 276	
choline, TMA and TMAO, which is consistent with the fact that L-carnitine and betaine are 277	
minor substrates compared to choline for gut bacterial synthesis of TMA[41]. Choline and 278	
TMAO were modestly correlated whereas serum TMA and TMAO concentrations were 279	
clearly anti-correlated (Supplementary Fig. 1). The PC3/PC4 biplot summarized 36% of 280	
variance and was mainly influenced by choline and TMAO (Fig. 5B).  281	
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4. Discussion 282	
We have developed and validated a single method for MS-based simultaneous quantitative 283	
analysis of five methylamines involved in a metabolic pathway underlying functional cross-284	
talk between gut microbiome and host genome and involved in various metabolic disease 285	
processes. Unexpected anticorrelation between concentrations of TMAO, associated with 286	
cardiovascular risk in several studies, and TMA, which is a product of gut microbial 287	
metabolism, provides a biological rationale for broadening quantitative methylamine profiling 288	
at pathway level in order to gain more detailed biological information on these important 289	
compounds. 290	
Components of the methylamine metabolic pathway illustrate the importance of functional 291	
symbiotic relationships between gut microbes and the host and their contribution to 292	
mammalian metabolic regulations and genome expression in health and disease. TMA can be 293	
generated by intestinal microbial transformation of dietary constituents, including L-carnitine, 294	
choline and betaine. TMA is then absorbed by the host and metabolized into TMAO in the 295	
liver by a flavin monooxygenase (FMO3) [42]. A targeted analytical strategy designed to 296	
monitor in clinical environment coordinated changes in serum concentration of these 297	
compounds simultaneously has therefore great potential to investigate global regulations of 298	
the relevant pathway in patients. 299	
We have demonstrated the specificity, sensitivity and robustness of our MS method coupled 300	
with HILIC chromatography. HILIC is a variant of normal phase liquid chromatography (NP-301	
LC) for analytes eluted near the void on reverse phase (RP-LC). In contrast to RP-LC, 302	
compounds are eluted by increasing the percentage of polar mobile phase in HILIC columns. 303	
Among all the advantages of using HILIC over conventional RP-LC and NP-LC, the use of 304	
expensive ion pair reagents in mobile phases is not required and it can be conveniently 305	
coupled with mass spectrometry. For these reasons HILIC has become increasingly popular 306	
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because it has progressively been found useful for the analysis of polar drugs, metabolites and 307	
biologically important compounds in complex matrices [43] including quaternary ammonium 308	
compounds [29, 33]. 309	
Metabolite compounds can be detected in MS [29] or MS/MS [16, 30] experiments with 310	
single or triple quadrupole instruments and recent breakthrough in LC-MS/MS has promoted 311	
the use of this type of instrument in clinical laboratories [31]. When compounds do not 312	
fragment specifically or not at all, LC-MS/MS can be limited when compared to high-313	
resolution mass spectrometry (HRMS). Many studies have compared analytical performances 314	
of HRMS and tandem mass spectrometry, finding similar advantages in terms of linearity, 315	
limits of detection and precision for both systems, but higher specificity for low molecular 316	
compounds for HRMS [32]. Despite good performances of LC-MS/MS for routine diagnostic, 317	
LC-HRMS offers higher mass resolution than quadrupole systems, avoiding false negative. 318	
Moreover, it offers the opportunity to screen targeted analytes as well as non-a-priori selected 319	
substances with high-selectivity. 320	
We have also carefully evaluated matrix effect, which is frequently described in MS-based 321	
analyses [34], even though the exact underlying mechanisms remain unknown. Reduced 322	
analyte response with increasing compound concentration was the first evidence of this well 323	
recognized phenomenon [35]. One of the hypotheses to explain matrix effect is that it is due 324	
to competition between the targeted compound and co-eluting endogen components. The 325	
main techniques to assess matrix effect are post-column infusion and post-extraction addition 326	
[36, 37]. The latter, which we chose to apply, is based on analyte response comparison of 327	
spiked serum samples processed according to the sample preparation protocol and standard 328	
solutions prepared in the mobile phase.  329	
Matrix effects can be minimized by improving sample cleanup procedures or by altering 330	
chromatographic conditions to separate analytes of interest from matrix interferences [38]. 331	
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However, the most efficient way to overcome ionization effects associated with electrospray 332	
mass spectrometry experiment is through the utilization of stable isotopically labeled internal 333	
standard analogues with identical chemical and physical properties to the native analyte [39].  334	
Since internal standards follow all steps of the sample preparation process, it helps correct for 335	
variations in sample preparation and compensates for variability during ionization. However, 336	
in some cases, a deuterium labeled internal standard has demonstrated differing ionization 337	
potential compared to the analyte, due to the slight shift in retention time between analyte and 338	
internal standard, and the retention relationship with the co-eluting endogenous material [40]. 339	
Optimized chromatographic gradients are therefore required to overcome this issue, as 340	
described by Zhang and Wujci [39]. In our study, the chromatographic gradient ensured 341	
identical retention times between analyte and its deuterium internal standard. 342	
In conclusion, we propose a UPLC-HRMS method for methylamine assay in biological 343	
samples, which shows performance in good agreement with observed concentrations in 344	
human serum and was successfully applied to metabolite quantification in clinical samples to 345	
establish the range of serum concentrations in control individuals. The high-throughput nature 346	
of this method should facilitate clinical applications of biomarker quantitative analyses in 347	
various analytical matrices and human disease contexts. 348	
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Table 1: Chemical structures and properties of target analytes, and their corresponding isotope labeled standards. 424	
 425	
Compound name and abbreviation Standard type Molecular formula                 Chemical structure log P 
Trimethylamine (TMA) Target analyte C3H9N 
	
	
	
0.06 
Trimethylamine-13C3,15N  (TMA-13C3,15N) 
Isotope-labeled 
internal standard 
13C3H915N 	 - 
Trimethyamine N-Oxide (TMAO) Target analyte C3H10NO  -2.57 
Trimethylamine-oxide D9 (TMAO-D9) 
Isotope-labeled 
internal standard C3H1D9NO 
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20	
	
L-Carnitine Target analyte C7H16NO3 
 
-4.52 
L-Carnitine-D3  
Isotope-labeled 
internal standard C6H13CD3NO3 
 
- 
Betaine Target analyte C5H12NO2 
 
-3.25 
Betaine-D3 
Isotope-labeled 
internal standard C4H9CD3NO2 - 
Choline Target analyte C4H12NO2 -3.22 
Choline-1,1,2,2-D4 
Isotope-labeled 
internal standard C4H12D4NO2 - 
CH2 CH2
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O
OH
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Table 2: Analysis of spiked human serum demonstrates the performance of the methylamine method. Linearity, limit of detection and 426	
quantification, recovery, precision (repeatability and reproducibility), accuracy were assessed. ILOD, instrument limits of detection; MLOD, 427	
method limits of detection; RSD, Relative standard deviation. 428	
Compound   TMA TMAO Choline L-Carnitine Betaïne 
Linearity 
Mean intercept 0.016 0.001 0.003 -0.001 0.008 
Mean slope 0.025 0.020 0.032 0.039 0.036 
RSD (%) 14.324 1.507 1.397 1.513 1.530 
Mean R2 0.996 1.000 1.000 0.999 1.000 
Limit of detection  
ILOD (µmol/L) 0.010 0.005 0.002 0.010 0.010 
MLOD (µmol/L) 0.050 0.025 0.010 0.050 0.050 
Mean recovery (RSD %)  5 µmol/L 93 (2) 111 (3) 87 (10) 97 (4) 98 (7) 
Repetability (RSD %) 
Concentration spiked RSD (%) 
1 µmol/L 6 5 16 8 12 
5 µmol/L 2 3 10 4 7 
10 µmol/L 3 3 3 3 4 
Accuracy  
Endogenous (µmol/L) 0.66 1.00 17.61 5.29 6.22 
Concentration spiked Concentration measured (RSD%) 
 1 µmol/L 0.80 0.99 0.80 1.10 1.01 
 5 µmol/L 4.65 5.56 4.36 4.86 4.91 
10 µmol/L 10.79 11.95 9.60 10.06 10.00 
Stability (freeze-thaw 
cycles) RSD (%) 1.5 3.6 4.6 4.8 5.1 
   429	
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Table 3: Demonstration of statistically significant matrix effects in quantitative analysis of all 430	
five metabolites tested in the mass spectrometry assay. Data from serum samples from 67 431	
control individuals were used. 432	
	
TMAO	 TMA	 Choline	 L.carnitine	 Betaine	
Model	1	 0.092	 0.576	 0.155	 0.583	 0.799	
Model	2	 2.97e-07	 0.887	 1.085e-16	 2.60e-15	 4.95e-15	
comparison	 0.092	 0.576	 0.155	 0.583	 0.799	
433	
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Legends to Figures 434	
Figure 1: Outlined representation of the methylamine pathway and Vant’hoff plot showing 435	
separation of TMA, TMAO, choline and L-carnitine from 90% acetonitrile (ACN). k 436	
retention factors are shown for L-carnitine, betaine, choline, TMA and TMAO as a function 437	
of the ACN percentage in the mobile phase. 438	
Figure 2: Illustration of chromatographic separation of serum L-carnitine, betaine, choline, 439	
TMA and TMAO. Mass spectrometry and chromatographic features are shown. 440	
Figure 3: Regression models following isotopic dilution for the five compounds of interest 441	
(A: TMAO, B: TMA, C: L-Carnitine, D: Betaine and E: Choline) demonstrate matrix effects. 442	
The area ratios of each analyte to the internal standard are shown on the y-axes and 443	
concentrations are on the x-axes. Data are shown for serum (     ) and solvent (     ). Results 444	
from analyses of regression models based on intensity ratio and metabolite concentration in 445	
solvent and serum are shown (E). 446	
Figure 4: Physiological variability of the metabolites in human serum. Ranges of serum 447	
concentration of betaine, L-carnitine, choline, TMA and TMAO were determined in human 448	
serum from 67 control subjects. 449	
Figure 5: TMA and TMAO concentrations are anti-correlated in human serum from control 450	
individuals. Correlation comparisons are shown for concentrations of betaine, L-carnitine, 451	
choline, TMAO and TMA in human serum. Data were obtained from serum samples from 67 452	
control individuals. Biplots following principal component analysis are shown for PC1 vs. 453	
PC2 (A) and for PC3 vs. PC4 (B). 454	
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Supplementary Figure 1. Regression analysis of the concentration of betaine, L-carnitine,
choline, TMAO and TMA in human serum. Data were obtained from serum samples from 67
control individuals. Correlation matrix (Pearson) was calculated.
